How much funding has Beam Therapeutics raised?

Beam Therapeutics has raised $528.0M in total funding, most recently a Growth Equity round.

When was Beam Therapeutics founded?

Beam Therapeutics was founded in 2017.

Where is Beam Therapeutics headquartered?

Beam Therapeutics is headquartered in Cambridge, Massachusetts, United States.

What industry is Beam Therapeutics in?

Beam Therapeutics operates in Biotech, Gene Editing, Healthcare, Therapeutics.

How many employees does Beam Therapeutics have?

Beam Therapeutics has 201-500 employees.

Beam Therapeutics

Q: Who are Beam Therapeutics's investors?

Beam Therapeutics's investors include F-Prime Capital, ARCH Venture Partners, Sixth Street.

IPO

Breaking new ground to advance science with the potential to change lives

Public · Cambridge, United States · Founded 2017 · $528.0M raised

Biotech

Gene Editing

Healthcare

Therapeutics

Headquarters: Cambridge, Massachusetts
Employees: 201–500
Founded: 2017
Business Model: B2B
Website: beamtx.com

Total Funding: $528.0M
Last Round: $100.0M Growth EquityFeb 2026
Rounds: 4
Type: Public

About

Beam Therapeutics is a clinical-stage biotech company pioneering base editing technology to develop precision genetic medicines. Their platform uses proprietary base editors delivered via nonviral, electroporation, and viral modalities to correct disease-causing mutations in DNA. The company's pipeline targets serious diseases including sickle cell disease, phenylketonuria, and alpha-1 antitrypsin deficiency.

Summary

Beam Therapeutics is a Biotech company based in Cambridge, United States, founded in 2017. It has raised $528.0M in total across 4 rounds, most recently a $100.0M Growth Equity round in Feb 2026. Investors include F-Prime Capital, ARCH Venture Partners and Sixth Street.

LinkedIn X (Twitter)